Insu Therapeutics Secures U.S. Patent for Needle-Free Insulin Delivery

The allowance covers a mucoadhesive dosage form designed to adhere to the inner cheek, facilitating the direct absorption of peptide medicines. This development strengthens the intellectual property foundation for the company’s lead programs, InsuTab and BuccaGLP, which aim to deliver insulin and semaglutide without the need for needles or restrictive fasting schedules.

Backed by an exclusive worldwide licence from the University of British Columbia, Insu Therapeutics is positioning its platform to address a rapidly expanding market. With Hydreight Technologies providing a strategic path for future distribution across the United States, the company is moving to translate its proof-of-concept research into clinical-stage products. While the patent milestone validates the technology's design, the candidates remain in the investigational phase and require further regulatory approval before reaching the market.